factor XI inhibitor - Bayer AG

factor XI inhibitor

Ph. II candidate for CV (fibrillation, stroke, MI)

related to previous series

Br. J. Clin. Pharmacol.

Bayer AG

asundexian (BAY2433334) is a reversible Factor XIa active site inhibitor previously disclosed at the 2021 EFMC-ISMC conference. This article highlights the Ph. I data of asundexian in healthy volunteers,…


 this content is exclusive to
Premium members

Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.